ESC 2026 | Heterogeneity in cardiac amyloidosis care across Europe: insights from a KOL survey

This is the question we want to answer, of course, and it’s important to let you know that these results are only preliminary. So I’ve had a look into all the answers that the survey, what the cardiologists, the key opinion leaders, they answered, and that’s what I have looked into to make this abstract, of course. But we have to do further evaluation. I’ll just elaborate a little bit on this because it’s very important that we are now currently actually making pathways on how the cardiac amyloidosis patients are treated and we still have to validate those pathways and we are going to do that with cardiologists, ask them if they agree or not and if there’s any well-known centers or cardiologists who really answer differently than them we also have to look into those but so that’s important to let you know. But about the question you asked, there are quite a lot of differences, so in my talk what I found that there is a few centers in each country that can treat ATTR cardiomyopathy and there’s a lot of difference between countries in Europe. And for instance in the southern part of Europe they stated, because I didn’t check it but they that’s how they replied, that there sometimes are up to 11 or 20 centers in one country who can treat their ATTR cardiomyopathy. In other countries, for instance, there’s only one center. So those are really, really big differences, but we really did not look into what was the reason for it, or are they all really treating centers, or is it just follow-up or so. So that’s what we still have to do but this just gives like a highlight or something we should focus on. So that’s one part another part that’s interesting is the time it took to start treatment so that’s the other part I looked into and there’s differences in that. So in the western part of Europe, in the northern part as well, time to disease treatment initiation is way shorter than it is in, for instance, Eastern Europe. And I also don’t really know why that is yet, but maybe there are rules, maybe there are things they have to do first after they diagnose the patient and then they can treat it. So there are some really interesting things and this is only like a very small part of the survey. So we have a lot more going on as well, but we still really have to evaluate it.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.